A new partnership between the Danish Export and Investment Fund (EIFO) and the Novo Nordisk Foundation will launch a company ...

According to data from eToro, leading the list was telehealth platform, Hims & Hers Health, which surged 85 per cent in ...

Teva Pharmaceutical Industries Limited’s TEVA shares have risen 21.6% in three months. Over the past few quarters, Teva has ...

A long-term investor in Apple (AAPL) might be perfectly thrilled at the stock's performance. It has returned 663% over the past 10 years, compared with a return of 261% for the S&P 500 SPX. And ...

Investing.com -- AI-related stocks topped trading activity on Robinhood U.K. in June, led by Nvidia (NASDAQ: NVDA ), CoreWeave and Applied Digital, according to the platform’s monthly report. Nvidia ...

Novo Nordisk NOVO.B 2.82% plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm's weight-loss drug, Wegovy.

Drugmaker Novo Nordisk said it is halting its agreement with telehealth company Hims & Hers after less than two months, citing deceptive marketing and the selling of knock-off versions of its b… ...

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...

Novo Nordisk and tech giant NVIDIA have joined forces on a new project that aims to speed up drug discovery using generative AI.

Bad blood is brewing among some major players in the weight loss world. Novo Nordisk, the creator of Ozempic and Wegovy, cut short its partnership with telehealth company Hims & Hers Health Inc ...